Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T14:40:35.078Z.
Calculation as of: 2026-10-06T14:40:35.078Z.
Quote observation: 2026-10-06T14:40:27.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 017b786e338061c10a4665063360519c0b30ae95494f37f63af909a19a8b52dc
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2018-03-29.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
EV/FCF RATIO AVG TTM
N/A
EV/FCF RATIO AVG 3Y
N/A
EV/FCF RATIO AVG 5Y
N/A
EV/FCF RATIO AVG 10Y
N/A
EV/FCF RATIO AVG 15Y
N/A
EV/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Adicet Bio, Inc. (ACET) | $60.43M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $58.77M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $59.76M | N/A | N/A | N/A | N/A |
| InterCure Ltd. (INCR)vs › | $63.02M | 14.40x | 12.61x | 12.61x | 118.68x |
| Kalaris Therapeutics Inc (KLRS)vs › | $63.41M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.20M | N/A | N/A | N/A | N/A |
| Alps Group Inc (ALPS)vs › | $64.05M | N/A | N/A | N/A | N/A |
| Aldeyra The (ALDX)vs › | $56.71M | N/A | N/A | N/A | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $64.56M | N/A | 54.90x | 54.90x | 54.90x |
| PDS Biotechnology Corporation (PDSB)vs › | $64.31M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/FCF RATIO |
|---|---|
| 2018-03-29 | 67.37x |
| 2018-03-28 | 73.25x |
| 2018-03-27 | 77.33x |
| 2018-03-26 | 75.59x |
| 2018-03-23 | 80.58x |
| 2018-03-22 | 88.98x |
| 2018-03-21 | 98.10x |
| 2018-03-20 | 99.18x |
| 2018-03-19 | 100.32x |
| 2018-03-16 | 99.60x |
| 2018-03-15 | 99.42x |
| 2018-03-14 | 100.38x |
| 2018-03-13 | 102.60x |
| 2018-03-12 | 105.30x |
| 2018-03-09 | 105.30x |
| 2018-03-08 | 106.98x |
| 2018-03-07 | 111.97x |
| 2018-03-06 | 113.11x |
| 2018-03-05 | 115.69x |
| 2018-03-02 | 116.29x |
| 2018-03-01 | 120.13x |
| 2018-02-28 | 126.91x |
| 2018-02-27 | 128.41x |
| 2018-02-26 | 133.51x |
| 2018-02-23 | 135.01x |
| 2018-02-22 | 127.81x |
| 2018-02-21 | 128.05x |
| 2018-02-20 | 126.91x |
| 2018-02-16 | 122.47x |
| 2018-02-15 | 119.23x |
| 2018-02-14 | 118.45x |
| 2018-02-13 | 119.41x |
| 2018-02-12 | 118.51x |
| 2018-02-09 | 111.91x |
| 2018-02-08 | 108.91x |
| 2018-02-07 | 107.22x |
| 2018-02-06 | 106.38x |
| 2018-02-05 | 111.55x |
| 2018-02-02 | 112.15x |
| 2018-02-01 | 110.41x |
| 2018-01-31 | 107.22x |
| 2018-01-30 | 104.34x |
| 2018-01-29 | 107.28x |
| 2018-01-26 | 111.19x |
